Pharmacokinetics and milk penetration of difloxacin after a long-acting formulation for subcutaneous administration to lactating goats.

07:48 EST 21st December 2014 | BioPortfolio

Summary of "Pharmacokinetics and milk penetration of difloxacin after a long-acting formulation for subcutaneous administration to lactating goats."

The single-dose disposition kinetics of difloxacin were determined in clinically normal lactating goats (n=6) after intravenous (IV) and subcutaneous (SC) administration and subcutaneous administration of a long-acting poloxamer 407 gel formulation (P407). Difloxacin concentrations were determined by HPLC with fluorescence detection. Minimum inhibitory concentrations of difloxacin against 14 strains of Staphylococcus aureus isolated from mastitic goats' milk in Spain were determined to compute pharmacodynamic surrogate markers. The concentration-time data were analyzed by compartmental and noncompartmental pharmacokinetic methods. Following SC and P407 administration, difloxacin achieved maximum milk concentrations of 1.34+/-0.12 and 2.97+/-1.18mg/L, respectively, at 4.00+/-0.00h (SC) and 3.60+/-0.89h (P407) after administration. The absolute bioavailabilities after SC and P407 administration were 81.74+/-15.60% and 72.58+/-20.45%, respectively. Difloxacin penetration from the blood into the milk was good and high concentrations were found in milk secretions. From these data, a 15mg/kg dose of difloxacin P407 would appear to be effective against Staphylococcus aureus isolated from mastitic goats' milk with minimum inhibitory concentrations

Affiliation

Department of Pharmacology, Faculty of Veterinary Medicine, University of Murcia, Campus de Espinardo, 30.071-Murcia, Spain.

Journal Details

This article was published in the following journal.

Name: Journal of dairy science
ISSN: 1525-3198
Pages: 3056-3064

Links

PubMed Articles [10193 Associated PubMed Articles listed on BioPortfolio]

Milk and Blood Pharmacokinetics of Tylosin and Tilmicosin following Parenteral Administrations to Cows.

The aim of this study is to determine the pharmacokinetics of tylosin and tilmicosin in serum and milk in healthy Holstein breed cows (n = 12) and reevaluate the amount of residue in milk. Following t...

Preclinical Evaluation of TMC-278 LA, a Long-acting Formulation of Rilpivirine, Demonstrates Significant Protection from Vaginal HIV Infection.

Comparison of pharmacokinetics and milk elimination of flunixin in healthy cows and cows with mastitis.

Objective-To determine whether pharmacokinetics and milk elimination of flunixin and 5-hydroxy flunixin differed between healthy and mastitic cows. Design-Prospective controlled clinical trial. Animal...

Novel extraction method of genomic DNA suitable for long-fragment amplification from small amounts of milk.

Isolation of genomic DNA is a prerequisite for assessment of milk quality. As a source of genomic DNA, milk somatic cells from milking ruminants are practical, animal friendly, and cost-effective sour...

A 12-week subchronic intramuscular toxicity study of risperidone-loaded microspheres in rats.

Long-acting injectable formulations of antipsychotics have been an important treatment option to increase the compliance of the patient with schizophrenia by monitoring drug administration and identif...

Clinical Trials [3909 Associated Clinical Trials listed on BioPortfolio]

Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia

The purpose of this study is to explore the pharmacokinetics, safety and tolerability of a 4-week long-acting injectable (LAI) formulation of risperidone after single intramuscular (i.m.) ...

A Study of the Efficacy, Safety, and Quality of Life of Patients With Schizophrenia Receiving Treatment With a Long-acting Injectable Formulation of Risperidone

The purpose of this study is to evaluate the long-term effectiveness and safety of a long-acting injectable formulation of risperidone (an antipsychotic medication) in patients with schizo...

Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

Exenatide LAR is a long-acting release formulation of exenatide, which is a twice-daily dosage form currently under investigation as a potential treatment for people with type 2 diabetes m...

Open Label Study of a Single Dose of a New Extended Long Acting Formulation of Octreotide Pamoate in Healthy Volunteers

This study will assess the pharmacokinetic profile, safety and tolerability of an octreotide extended long-acting formulation after a single dose in humans. It will investigate the profile...

High Dose Somatostatin Analogues in Neuroendocrine Tumors

Octreotide (OCT) is a somatostatin analogue (SSA) available in a long-acting formulation, conventionally administered every 28 days at the maximum dose of 30 mg. Together with lanreotide, ...

Medical and Biotech [MESH] Definitions

Insulin formulation containing substance which delays or retards time period of the absorption of insulin.

Allergic reaction to milk (usually cow's milk) or milk products. MILK HYPERSENSITIVITY should be differentiated from LACTOSE INTOLERANCE, an intolerance to milk as a result of congenital deficiency of lactase.

One of the long-acting ANTIPSYCHOTIC AGENTS used for maintenance or long-term therapy of SCHIZOPHRENIA and other PSYCHOTIC DISORDERS.

The processes of milk secretion by the maternal MAMMARY GLANDS after PARTURITION. The proliferation of the mammary glandular tissue, milk synthesis, and milk expulsion or let down are regulated by the interactions of several hormones including ESTRADIOL; PROGESTERONE; PROLACTIN; and OXYTOCIN.

Long acting sulfonamide antibacterial agent.

Search BioPortfolio:
Loading